Antiemetics And Antinauseants

This article discusses the use of antiemetics and antinauseants in clinical trials for patients with locally advanced or metastatic hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. These medications are being studied as part of a comprehensive treatment approach to manage side effects and improve patient quality of life during cancer therapy.

Table of Contents

What are Antiemetics and Antinauseants?

Antiemetics and antinauseants are medications designed to prevent or reduce nausea and vomiting. These drugs play a crucial role in managing various medical conditions and are often used as supportive treatments in cancer therapy[1].

Medical Conditions Treated

While the primary focus of antiemetics and antinauseants is to control nausea and vomiting, they are particularly important in the context of cancer treatment. In the clinical trial described, these medications are being used as auxiliary treatments for patients with locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer[1].

Let’s break down these terms:

  • Locally advanced breast cancer: Cancer that has spread from the breast to nearby tissues or lymph nodes but not to distant parts of the body.
  • Metastatic breast cancer: Cancer that has spread beyond the breast and nearby lymph nodes to other parts of the body.
  • Hormone receptor (HR)-positive: The cancer cells have receptors for either estrogen or progesterone, which can promote cancer growth.
  • HER2-negative: The cancer cells do not have high levels of a protein called HER2, which can promote cancer growth.

Patients with this type of breast cancer often receive various treatments that can cause nausea and vomiting as side effects. Antiemetics and antinauseants help manage these symptoms, improving the patient’s quality of life during treatment[1].

Administration and Usage

According to the clinical trial information, antiemetics and antinauseants are typically administered through injection[1]. This method of administration is often preferred in cancer treatment settings as it can provide rapid relief and is useful when patients have difficulty taking oral medications due to severe nausea.

Current Clinical Trials

The clinical trial described is studying a new treatment (Sacituzumab Govitecan) for HR+/HER2- metastatic breast cancer. While antiemetics and antinauseants are not the primary focus of this study, they are listed as auxiliary medications[1]. This highlights their important role in supporting patients through cancer treatments by managing side effects.

Important Considerations

When using antiemetics and antinauseants, patients should be aware of the following:

  1. Dosage: The dosage is typically determined by your healthcare provider based on your specific needs and the severity of your symptoms.
  2. Duration: In the clinical trial, the maximum treatment period for auxiliary medications like antiemetics is listed as 1 day, suggesting they may be used as needed rather than continuously[1].
  3. Side effects: Like all medications, antiemetics and antinauseants can have side effects. These may vary depending on the specific drug used.
  4. Interaction with other medications: Always inform your healthcare provider about all medications you’re taking to avoid potential drug interactions.

Remember, while antiemetics and antinauseants can significantly improve comfort during cancer treatment, they are supportive medications and not a treatment for cancer itself. Always follow your healthcare provider’s instructions and report any concerns or severe side effects promptly.

Aspect Details
Study Type Randomized, Open-label, Phase 3 Study
Main Drug Sacituzumab Govitecan
Comparison Treatment of Physician’s Choice
Patient Population HR+/HER2- Metastatic Breast Cancer patients who have received endocrine therapy
Primary Endpoint Progression-Free Survival (PFS)
Secondary Endpoints Overall Survival (OS), Objective Response Rate (ORR), Quality of Life measures
Inclusion Criteria Highlights 18+ years old, measurable disease, HR+/HER2- status, prior endocrine therapy
Exclusion Criteria Highlights Recent disease progression, active CNS metastases, significant cardiovascular disease
Role of Antiemetics and Antinauseants Supportive care to manage treatment-related side effects

Ongoing Clinical Trials on Antiemetics And Antinauseants

  • Study Comparing Sacituzumab Govitecan with Other Treatments for Patients with HR+/HER2- Metastatic Breast Cancer After Endocrine Therapy

    Not recruiting

    1 1 1 1
    Austria Belgium Czechia France Germany Greece +5

Glossary

  • Antiemetics and Antinauseants: Medications used to prevent or reduce nausea and vomiting, often associated with cancer treatments like chemotherapy.
  • Hormone Receptor-Positive (HR+): A type of breast cancer where the cancer cells have receptors for either estrogen or progesterone hormones, which can promote cancer growth.
  • HER2-Negative (HER2-): Breast cancer cells that do not have high levels of a protein called human epidermal growth factor receptor 2, which promotes cancer cell growth.
  • Metastatic Breast Cancer: Breast cancer that has spread beyond the breast to other parts of the body.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with the disease without it getting worse.
  • RECIST: Response Evaluation Criteria in Solid Tumors, a set of rules used to measure how well a cancer patient responds to treatment.
  • Endocrine Therapy: A type of cancer treatment that adds, blocks, or removes hormones to slow or stop the growth of cancer cells that use hormones to grow.
  • Quality of Life (QoL): A measure of an individual's overall well-being and ability to function in daily life, often assessed in cancer patients undergoing treatment.

References

  1. http://clinicaltrials.eu/trial/study-comparing-sacituzumab-govitecan-with-other-treatments-for-patients-with-hr-her2-metastatic-breast-cancer-after-endocrine-therapy/